ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Phase 3 BREAKWATER Study Safety Lead-In: Encorafenib + Cetuximab + Chemo for BRAFV600E mCRC

663 views
February 1, 2023
Comments 0
Login to view comments. Click here to Login